Education
About Us
Working with TipRanks
Follow Us
Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
XVIVO Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr167.70 - kr533.00
Previous CloseN/A
Volume6.25K
Average Volume (3M)187.87K
Market Cap
$5.28B
Enterprise Valuekr8.71B
Total Cash (Recent Filing)$323.00M
Total Debt (Recent Filing)$110.81M
Price to Earnings (P/E)47.4
Beta1.31
Next Earnings
Oct 23, 2025EPS Estimate
0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding31,499,470
10 Day Avg. Volume213,421
30 Day Avg. Volume187,872
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue10.59
Enterprise Value/Gross Profit14.14
Enterprise Value/Ebitda101.32
Forecast
1Y Price Target
$195.00Price Target Upside16.28% Upside
Rating ConsensusHold
Number of Analyst Covering0
Xvivo Perfusion AB News
XVIVO FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr167.70 and its highest was kr533.00 in the past 12 months.
What is Xvivo Perfusion AB’s market cap?
Xvivo Perfusion AB’s market cap is $5.28B.
When is Xvivo Perfusion AB’s upcoming earnings report date?
Xvivo Perfusion AB’s upcoming earnings report date is Oct 23, 2025 which is in 51 days.
How were Xvivo Perfusion AB’s earnings last quarter?
Xvivo Perfusion AB released its earnings results on Jul 11, 2025. The company reported kr0.05 earnings per share for the quarter, missing the consensus estimate of kr0.617 by -kr0.567.
Is Xvivo Perfusion AB overvalued?
According to Wall Street analysts Xvivo Perfusion AB’s price is currently Undervalued.
Does Xvivo Perfusion AB pay dividends?
Xvivo Perfusion AB does not currently pay dividends.
What is Xvivo Perfusion AB’s EPS estimate?
Xvivo Perfusion AB’s EPS estimate is 0.58.
How many shares outstanding does Xvivo Perfusion AB have?
Xvivo Perfusion AB has 31,499,470 shares outstanding.
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Xvivo Perfusion AB reported an EPS of kr0.05 in its last earnings report, missing expectations of kr0.617. Following the earnings report the stock price went down -32.687%.
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
Currently, no hedge funds are holding shares in SE:XVIVO
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (XVIVO) is a Swedish medical technology company that specializes in organ preservation and perfusion solutions for transplantation. The company focuses on improving the viability of organs for transplant through innovative technologies and products, primarily targeting the fields of lung, kidney, and liver transplantation. XVIVO's core products include organ preservation solutions, perfusion devices, and associated services that enhance the effectiveness of transplant procedures and improve patient outcomes.
XVIVO Company Deck
XVIVO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong quarter with significant growth in the Thoracic and Liver segments, complemented by successful heart trials and strategic acquisitions. However, challenges in the Abdominal and Services segments, along with hurdles in launching Kidney Assist Transport in the U.S., balanced the overall sentiment.View all SE:XVIVO earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
5.52%
Mutual Funds
― Other Institutional Investors
91.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---